The advance purchase agreement will allow EU member states to secure up to 200 million additional doses, the company said.
Johnson & Johnson is developing and testing Janssen's COVID-19 vaccine candidate via a multicountry single-dose phase III trial that started in September; a second phase III study with a two-dose protocol will start later this year. The vaccine includes Janssen's AdVac technology, which it also used to develop an Ebola vaccine and is the basis for that firm's HIV, RSV, and Zika vaccine candidates.
The company also plans to set aside up to 500 million vaccine doses for lower income countries, with delivery in mid-2021 following regulatory approval, it said.
Copyright © 2020 scienceboard.net